Please login to the form below

Not currently logged in
Email:
Password:

Call for rigorous diabetes drug tests

A panel of experts has recommended to the US Food and Drug Administration that drugs to control Type II diabetes be subjected to more intensive cardiovascular trials
A panel of experts has recommended to the US Food and Drug Administration (FDA) that drugs to control Type II diabetes be subjected to more intensive cardiovascular trials.

The advisory panel voted 14-2 to recommend that all manufacturers of diabetes drugs conduct trials lasting up to five years to detect cardiovascular problems such as heart attacks and strokes.

The panel agreed that the requirement should apply to all experimental drugs. Several panel members were in favour of beginning this study before the drug's approval and completing it when it reaches the market. However, at least one panellist doubted these studies' ability to uncover heart risks and raised concern about the delay these additional trials may cause to important medical breakthroughs.

In most circumstances, the FDA will implement the recommendations of its advisory panels, although it has no legal obligation to do so.

According to Reuters, FDA officials said although diabetes drugs that work by controlling blood-sugar levels, help prevent some complications such as eye and kidney damage, there is no evidence that any diabetes drug reduces heart disease - the primary cause of death in diabetics.

3rd July 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...
Deal Watch January 2018
...

Infographics